# Long-term Safety Study of BHV-3500 (Zavegepant*) for the Acute Treatment of Migraine

> **NCT04408794** · PHASE2,PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 974 (actual)

## Conditions studied

- Acute Migraine

## Interventions

- **DRUG:** Zavegepant (BHV-3500)

## Key facts

- **NCT ID:** NCT04408794
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-29
- **Primary completion:** 2021-12-09
- **Final completion:** 2021-12-23
- **Target enrollment:** 974 (ACTUAL)
- **Last updated:** 2023-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04408794

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04408794, "Long-term Safety Study of BHV-3500 (Zavegepant*) for the Acute Treatment of Migraine". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04408794. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*